fincash logo SOLUTIONS
EXPLORE FUNDS
CALCULATORS
LOG IN
SIGN UP

Fincash » Search » Glaxosmithkline Pharmaceuticals Ltd

Glaxosmithkline Pharmaceuticals Ltd

Updated on November 6, 2019

Stock/Share Code - GLAXO

GSK India is committed to providing medicines that will improve peoples quality of life and truly make a difference to patients. Their ultimate goal is to leverage the power of science through new inn...Read more

Below is the details of GLAXO Glaxosmithkline Pharmaceuticals Ltd

Market Cap₹20,586 Cr.
Current Price ₹1,620 as on 11 Nov 19
52 Week High / Low Price₹1,812 / ₹1,130
Face Value₹10
Stock P/E46.47
Book Value₹126.47
Dividend Yield1.65 %
ROCE31.15 %
ROE19.96 %
Sales Growth (3yrs)3.45 %
SectorPharmaceuticals
IndustryPharmaceuticals - Multinational
Listed onBSE  AND  NSE
Company WebsiteCompany Website
Pros: Company has reduced debt. Company is virtually debt free. Company has been maintaining a healthy dividend payout of 79.78%
Cons: Stock is trading at 9.61 times its book value The company has delivered a poor growth of 4.21% over past five years.

Glaxosmithkline Pharmaceuticals Ltd Price Chart

Glaxosmithkline Pharmaceuticals Ltd Price Chart

Glaxosmithkline Pharmaceuticals Ltd Peer Comparison in Pharmaceuticals

S.No. Name CMP Rs. P/E Mar Cap Rs.Cr. Div Yld % NP Qtr Rs.Cr. Qtr Profit Var % Qtr Sales Var % Sales Qtr Rs.Cr. ROCE %
1. Glaxosmi. Pharma ₹15.2 46.47 ₹20,586.22 Cr. 1.65 ₹113.46 Cr. 20.84 7.12 788.02 31.15
2. Glaxosmi. Pharma ₹15.2 48.35 ₹20,586.22 Cr. 1.65 ₹113.54 Cr. 27.17 7.11 787.97 31.11
3. Abbott India ₹11,698.85 40.10 ₹19,440.78 Cr. 0.71 ₹116.94 Cr. 41.92 18.22 998.89 37.36
4. Sanofi India ₹6,613.25 36.36 ₹14,138.35 Cr. 1.37 ₹97.4 Cr. -2.21 9.41 747.90 28.84
5. Pfizer ₹3,995.1 29.74 ₹13,382.81 Cr. 0.77 ₹112.81 Cr. 22.83 6.26 544.40 23.22
6. Proc. Gam. Heal. ₹138.8 8.01 ₹6,830.07 Cr. 10.69 ₹44.08 Cr. -8.76 6.06 233.63 78.16
7. Astrazeneca Phar ₹2,541.8 67.59 ₹4,701.63 Cr. 0.00 ₹21.52 Cr. 236.78 26.71 204.56 26.51
8. Novartis India ₹67.15 62.57 ₹1,401.57 Cr. 1.76 ₹0.79 Cr. -92.10 -20.85 109.31 7.58

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Glaxosmithkline Pharmaceuticals Ltd Fundamentals

Quarterly Results

Quarterly reports are issued by companies every three months. Most companies have a financial year-end of Mar. 31 and quarters that end on June 30, Sept. 30, Dec. 31 and March 31.

Standalone Figures in Rs. Crores

Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019
Sales799706760583836704749736816825751788
YOY Sales Growth %11.37%-5.9%7.56%-17.36%4.65%-0.35%-1.45%26.21%-2.39%17.25%0.35%7.12%
Expenses658654623563644562594595651688608623
Material Cost %45.23%50.55%47.51%46.48%45.03%39.81%41.82%43.06%42.77%46.35%40.61%41.98%
Employee Cost %15.89%17.04%15.49%22.67%16.22%17.6%17.59%17.12%17.09%15.21%19.45%18.12%
Operating Profit1415213720192142155140165137144165
OPM %18%7%18%3%23%20%21%19%20%17%19%21%
Other Income18334126151218103456931
Interest000000000001
Depreciation778881391112121419
Profit before tax1527817038199140164138156170199176
Tax %35%32%34%31%35%36%35%36%36%33%38%36%
Net Profit9953113261309010689101113123113
EPS in Rs5.853.156.661.567.705.296.235.235.956.677.266.70
NotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotesNotes

Profit & Loss

The profit and loss (P&L) statement is a financial statement that summarizes the revenues, costs and expenses incurred during a specified period, usually a fiscal quarter or year. The P&L statement is synonymous with the income statement. These records provide information about a company's ability or inability to generate profit" by increasing revenue, reducing costs or both. Some refer to the P&L statement as a statement of profit and loss, income statement, statement of operations, statement of financial results or income, earnings statement or expense statement.

Standalone Figures in Rs. Crores

Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019TTM
Sales1,5591,6651,8732,1122,3762,6262,5463,2882,8262,9032,8723,1293,181
Sales Growth %2.22%6.8%12.45%12.76%12.51%10.55%-3.06%29.12%-14.03%2.72%-1.08%8.94%%
Expenses1,0901,1571,2361,3741,5931,8112,0252,6612,3632,4852,3632,5652,569
Material Cost %40.31%38.89%36.96%36.8%38.24%41.8%45.47%45.79%43.44%48.01%43.21%43.26%%
Manufacturing Cost %4.6%4.63%4.5%4.33%4.26%3.32%4.51%4.75%8.3%4.69%4.77%4.57%%
Employee Cost %9.5%10.11%10.89%11.11%12.1%14.98%14.22%15%15.69%16.64%18.23%17.17%%
Other Cost %15.48%15.84%13.62%12.85%12.47%8.87%15.32%15.41%16.19%16.26%16.09%16.99%%
Operating Profit470508637737782815521627463418508563612
OPM %30%31%34%35%33%31%20%19%16%14%18%18%19%
Other Income339311153122-1634922814813812071150147
Interest1101000000011
Depreciation16161618201820252527384956
Profit before tax791802773841599847729749576511542664701
Tax %32%28%34%33%28%32%31%37%35%34%35%36%
Net Profit538577512564431577502472375337352425450
EPS in Rs28.6830.6427.8730.1421.8630.3225.4317.1915.7519.8820.7825.1126.58
Dividend Payout %57%59%50%60%89%73%84%112%113%75%84%80%

Compounded Sales Growth

  • 10 Years:: 6.51%
  • 5 Years:: 4.21%
  • 3 Years:: 3.45%
  • TTM:: 5.17%

Compounded Profit Growth

  • 10 Years:: -1.47%
  • 5 Years:: -2.69%
  • 3 Years:: 4.16%
  • TTM:: 8.71%

Return on Equity

  • 10 Years:: 24.33%
  • 5 Years:: 19.01%
  • 3 Years:: 17.04%
  • Last Year:: 19.96%

Balance Sheet

A balance sheet is a financial statement that reports a company's assets, liabilities and shareholders' equity at a specific point in time, and provides a basis for computing rates of return and evaluating its capital structure. It is a financial statement that provides a snapshot of what a company owns and owes, as well as the amount invested by shareholders. It is used alongside other important financial statements such as the income statement and statement of cash flows in conducting fundamental analysis or calculating financial ratios.

Standalone Figures in Rs. Crores

Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Share Capital8585858585858585858585169
Equity Capital84.784.784.784.784.784.784.784.784.784.784.7169.41
Reserves1,2761,4561,6741,8461,8351,9251,9321,7672,1201,9441,9951,973
Borrowings665555432211
Other Liabilities6477357078561,0921,0781,1331,3928731,0061,9001,790
Trade Payables226.3251.66291.37331.92198.34239.7281.9336.23395.58519.48642.92479.68
Total Liabilities2,0142,2822,4722,7913,0173,0933,1553,2473,0803,0363,9813,933
Fixed Assets8790931099989100123204258325432
Gross Block266.71282.15289.18318.4271.66272.04299.08319.19228.36305.22408.14561.3
Accumulated Depreciation179.24191.75196.37209.47172.53182.63199.01196.1324.3247.1983.57129.69
CWIP5102191644621152686059231,003
Investments1,333752191160160103584854484825
Other Assets5881,4302,1672,5132,7422,8572,9352,9612,5552,1252,6862,475
Inventories205.96228.38253.02281.54330.14282.04342.4368.86521.66425.48500.18486.49
Trade receivables37.7757.9453.7347.0285.31115.996.39100.32126.57170.8146.96120.49
Cash Equivalents154.99906.541672.61948.081984.092038.782027.141898.021377.68882.231279.691155.33
Loans n Advances188.88236.87187.35236.83180.16220.52222.7291.02232277.28355.47313.47
Other Assets etc0000162.2199.87246.43302.35296.72368.84403.78398.73
Total Assets2,0142,2822,4722,7913,0173,0933,1553,2473,0803,0363,9813,933

Cash Flows

Cash flow is the net amount of cash and cash-equivalents being transferred into and out of a business. At the most fundamental level, a company’s ability to create value for shareholders is determined by its ability to generate positive cash flows, or more specifically, maximize long-term free cash flow.

Standalone Figures in Rs. Crores

Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
Cash from Operating Activity307319503468322294267341138232475401
Profit from operations550.62597.95673.48762.23767.87815.97522.78628.11478.55419.93512.64628.29
Working Capital Changes10.71-33.2522.2111.06-74.0538.791.66-30.17-125.04-29.47163.69-7.58
Taxes paid-246.81-240.23-177.43-304.67-309.3-313.8-242.05-250.13-215.24-158.19-201.56-219.64
Cash from Investing Activity112787655102368-93198178499303-107-144
Fixed Assets Purchased-15.33-23.88-30.37-21.39-42.54-39.08-58.45-163.12-232.32-304.43-403.38-291.28
Fixed Assets Sold240.420.279.50.772.460.3427.920.7324.1346.43570.0748.05
Investments purchased-193.76-58.060000000000
Investments sold0785.35560.130.0105744.91100000
Cash from Financing Activity-299-355-392-294-392-437-490-497-638-511-307-358
Proceeds from Borrowings0.2300000000000
Repayment of Borrowings0-0.12-0.23-0.26-0.260000000
Interest Paid-0.63-0.32-0.35-0.68-0.61-0.33-0.33-0.47-0.42-0.25-0.19-0.55
Dividends Paid-261.29-303.05-336.67-253.03-337.67-378.15-421.38-423.52-529.39-423.52-254.11-296.46
Net Cash Flow120751766275298-236-2522-12561-102

Ready to Invest?
Talk to our investment specialist
Disclaimer:
By submitting this form I authorize Fincash.com to call/SMS/email me about its products and I accept the terms of Privacy Policy and Terms & Conditions.

Ratios

Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019
ROCE %51%47%46%47%48%50%35%41%28%22%26%31%
Debtor Days9131081316141116211914
Inventory Turnover6.987.677.787.907.778.588.159.246.356.136.206.34

Announcements & News

Recent Announcements

Annual Reports

How to Invest in Mutual Funds SIP Online?

  1. Open Free Investment Account for Lifetime at Fincash.com.
  2. Complete your Registration and KYC Process
  3. Upload Documents (PAN, Aadhaar, etc.). And, You are Ready to Invest! Get Started
  4. Invest in Mutual Funds which invests in Glaxosmithkline Pharmaceuticals Ltd & Get More Returns than Bank Deposit

Disclaimer:
All efforts have been made to ensure the information provided here is accurate as per time to time filling by company to exchanges. However, no guarantees are made regarding correctness of data. Investors are advised to validate/check information with exchanges or companies website before making any investment decisions.